Terms: = Lymphoma AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
14 results:
1. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological and molecular features of indolent natural killer-cell lymphoproliferative disorder of the gastrointestinal tract.
Yi H; Li A; Ouyang B; Da Q; Dong L; Liu Y; Xu H; Zhang X; Zhang W; Jin X; Gu Y; Wang Y; Liu Z; Wang C
Histopathology; 2023 Mar; 82(4):567-575. PubMed ID: 36494712
[TBL] [Abstract] [Full Text] [Related]
3. Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell lymphoma.
Lone W; Bouska A; Sharma S; Amador C; Saumyaranjan M; Herek TA; Heavican TB; Yu J; Lim ST; Ong CK; Slack GW; Savage KJ; Rosenwald A; Ott G; Cook JR; Feldman AL; Rimsza LM; McKeithan TW; Greiner TC; Weisenburger DD; Melle F; Motta G; Pileri S; Vose JM; Chan WC; Iqbal J
Clin Cancer Res; 2021 Nov; 27(21):6039-6053. PubMed ID: 34426436
[TBL] [Abstract] [Full Text] [Related]
4. Aggressive B-cell lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract] [Full Text] [Related]
5. Targeting steroid resistance in T-cell acute lymphoblastic leukemia.
De Smedt R; Morscio J; Goossens S; Van Vlierberghe P
Blood Rev; 2019 Nov; 38():100591. PubMed ID: 31353059
[TBL] [Abstract] [Full Text] [Related]
6. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract] [Full Text] [Related]
7. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract] [Full Text] [Related]
8. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract] [Full Text] [Related]
9. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
[TBL] [Abstract] [Full Text] [Related]
10. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract] [Full Text] [Related]
11. Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
Wang B; Fang J; Qu L; Cao Z; Zhou J; Deng B
Tumour Biol; 2015 Sep; 36(9):6901-8. PubMed ID: 25851347
[TBL] [Abstract] [Full Text] [Related]
12. Deregulated MIR335 that targets mapk1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia.
Yan J; Jiang N; Huang G; Tay JL; Lin B; Bi C; Koh GS; Li Z; Tan J; Chung TH; Lu Y; Ariffin H; Kham SK; Yeoh AE; Chng WJ
Br J Haematol; 2013 Oct; 163(1):93-103. PubMed ID: 23888996
[TBL] [Abstract] [Full Text] [Related]
13. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract] [Full Text] [Related]
14. [p38 mitogen-activated protein kinase mediates glucocorticoid receptor function induced by dexamethasone in acute lymphoblastic leukemia cells].
He L; Li D; Hou KZ; Liu YP
Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):687-91. PubMed ID: 18021564
[TBL] [Abstract] [Full Text] [Related]
